Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948090 · ClinicalTrials.gov registry record · Phase 2
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
A Phase 2 study of Lymphoma, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
- 20
- Study locations
NCT00948090: Completed Phase 2 study of Lymphoma, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00948090 is a Phase 2 study of Lymphoma that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 207 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00948090, a Phase 2 study of Lymphoma, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.
Primary Outcome
The time of Progression-Free Survival (PFS) was defined as the time from transplantation to the occurrence of the event that was death or first recurrence of progressive disease.
Conditions Studied
Interventions
- DRUG IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Study Locations (20)
California
- Alta Bates Summit Medical Center - Berkeley
- Scripps Clinic - La Jolla
- UCSD Medical Center BMT Program - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- Sutter Cancer Center - Sacramento
- University of California, Davis Medical Center - Sacramento
- University of California San Francisco Medical Center - San Francisco
Illinois
- University of Illinois Cancer Center - Chicago
- The University of Chicago - Chicago
- Loyola University Chicago - Maywood
Alabama
- University of Alabama in Birmingham - Birmingham
Arizona
- Arizona Cancer Center - Tucson
Colorado
- Rocky Mountain Cancer Centers - Denver
Florida
- Florida Hospital Cancer Institute - Orlando
Georgia
- Emory University - Atlanta
Indiana
- Bone Marrow and Stem Cell Transplant Program - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT00948090 record still lists
NCT00948090 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen) is the first listed.
NCT00948090 names 20 study sites across 12 states, led by California, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT00948090 about?
NCT00948090 is a clinical study titled "PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients". This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.
What is the current status of trial NCT00948090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2010-01. Estimated completion is 2013-06.
What conditions does trial NCT00948090 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00948090?
The interventions under investigation include: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen) (DRUG).
Who is sponsoring clinical trial NCT00948090?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00948090 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00948090's enrollment target sits among peer trials
207 47th of 299 higher than 253 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia